Exicure (DE:2H0)
NASDAQ:2H0
2H0 Stock Chart & Stats
€4.08
€0.00(0.00%)
At close: 4:00 PM EST
€4.08
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.48 - €8.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€24.37M
Enterprise Value€24.57M
Total Cash (Recent Filing)€3.75M
Total Debt (Recent Filing)€176.00K
Price to Earnings (P/E)―
Beta-1.40
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding6,373,915
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Leverage (debt Eliminated)Elimination of reported debt materially reduces interest and refinancing risk, improving financial flexibility. For a clinical-stage biotech, a debt-free balance sheet lengthens strategic optionality for licensing, partnerships, or milestone-driven funding without fixed debt service obligations.
Phase 2 Milestone / FDA SubmissionDelivery of a contractual Phase 2 milestone and FDA study report submission de-risks the program and unlocks near-term partner cash. It also adjusts economic terms with GPCR Therapeutics, increasing long-term participation and improving potential future non-dilutive revenue from sublicensing or collaborations.
Peer-reviewed Phase 2 Data PublishedPublication of positive Phase 2 results in a peer-reviewed journal strengthens scientific credibility and supports regulatory and partner discussions. Robust primary endpoint achievement and favorable tolerability are durable evidence assets that improve the asset's commercialization and partnering prospects over months.
Bears Say
Persistent Cash BurnConsistent and worsening negative operating and free cash flows indicate the business is not self-sustaining and will need external financing or partner-funded programs. This structural reliance increases dilution risk and can constrain R&D progression if capital markets or partners are limited.
Recurring Losses & Unstable RevenueA pattern of perennial losses and erratic, non-recurring revenue undermines margin sustainability and operating predictability. Without steady revenue streams or commercial products, long-term viability depends on infrequent milestone payments or financing, which is a fragile model for sustained R&D investment.
Top-management & Board TurnoverSimultaneous senior executive departures and board reshuffling introduce governance and execution risk during a critical clinical and financing phase. Leadership gaps and reliance on interim arrangements can delay strategic decisions, fundraising, and partnership negotiations, harming long-term program execution.
Exicure News
2H0 FAQ
What was Exicure’s price range in the past 12 months?
Exicure lowest stock price was €1.48 and its highest was €8.25 in the past 12 months.
What is Exicure’s market cap?
Exicure’s market cap is €24.37M.
When is Exicure’s upcoming earnings report date?
Exicure’s upcoming earnings report date is May 20, 2026 which is in 52 days.
How were Exicure’s earnings last quarter?
Exicure released its earnings results on Mar 25, 2026. The company reported -€0.394 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.394.
Is Exicure overvalued?
According to Wall Street analysts Exicure’s price is currently Overvalued.
Does Exicure pay dividends?
Exicure does not currently pay dividends.
What is Exicure’s EPS estimate?
Exicure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exicure have?
Exicure has 6,373,915 shares outstanding.
What happened to Exicure’s price movement after its last earnings report?
Exicure reported an EPS of -€0.394 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Exicure?
Currently, no hedge funds are holding shares in DE:2H0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Exicure
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Technical Analysis
Options Prices
Currently, No data available
---